Related references
Note: Only part of the references are listed.mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Heidi A. Lane et al.
CLINICAL CANCER RESEARCH (2009)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: A phase I/II trial
John D. Hainsworth et al.
CLINICAL GENITOURINARY CANCER (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Combination therapy of imatinib mesylate and interferon-α demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma:: Results of a single-institution phase II trial
Blase N. Polite et al.
CLINICAL GENITOURINARY CANCER (2006)
Phase II trial of imatinib (Gleevec (R)) in patients with metastatic renal cell carcinoma
J Vuky et al.
INVESTIGATIONAL NEW DRUGS (2006)
Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema
U Fuchs et al.
TRANSPLANTATION (2005)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The von Hippel-Lindau tumor suppressor gene and kidney cancer
WG Kaelin
CLINICAL CANCER RESEARCH (2004)
Expression of platelet-derived growth factor-αα receptor is associated with tumor progression in clear cell renal cell carcinoma
I Sulzbacher et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin
CC Hudson et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
